NEW YORK, NEW YORK, USA, September 16, 2021 /EINPresswire.com/ -- Koios Medical, a developer of artificial intelligence (AI) for early cancer detection and diagnostic accuracy, announced a strategic partnership with GE Healthcare with the launch of the company’s AI software available on GE’s InveniaTM ABUS 2.0 automated whole breast ultrasound scanning system, the only FDA-approved ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue.

Koios DS Breast is the only FDA-cleared cancer diagnosis software using AI on breast ultrasound images that works as an on-demand second opinion. The powerful combination gives Invenia ABUS users access to Koios DS AI algorithms trained for ultrasound image interpretation and assessment streamlining clinical workflow while improving clinical accuracy and patient care.

One out of every eight women in the US is expected to contract breast cancer over the course of her lifetime making breast cancer the leading cancer diagnosis in women worldwide. That risk is even greater for the more than 40 percent of women with dense breast tissue that requires automated or traditional ultrasound (or MRI) as a supplement to routine mammograms. Earliest possible detection is critical to increased survival rates while mitigating treatment complexity. Use of AI software in conjunction with ultrasound dramatically expands access to quality care and early diagnosis.

Koios DS BreastTM decision support software is approved and commercially available in the US and internationally integrated within GE’s LOGIQTM E10 Series and LOGIQ P-Series ultrasound system and GE CentricityTM PACS making the addition to the Invenia ABUS 2.0 system an extension of the power of AI broadly across GE’s ultrasound offering.

“Joining forces with the GE ABUS team and the Invenia ABUS 2.0 system now gives patients and physicians the speed, accuracy and peace of mind only made possible by combining AI with whole breast ultrasound. This combination is extremely inspiring. To know patients will experience fewer missed cancers and less avoidable procedures not to mention eliminating the anxiety imposed on women and their families from the millions of ‘false alarms’ every year motivates the Koios Medical team to continue innovating and integrating” says Koios Medical’s CEO Chad McClennan.

Advantages of this powerful combination include rapid and accurate diagnostic performance improving cancer detection rates, especially on women with dense breast tissue. Koios DS Breast, or Smart Ultrasound™, used in conjunction with Invenia ABUS 2.0 simultaneously reduces false positive interpretations resulting in fewer patient callbacks, less benign biopsy procedures and relieving patient stress while mitigating costly out of pocket expenses.

Ultrasound Homepage